Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · September 16, 2024

Efficacy of Atezolizumab, Pertuzumab, and High-Dose Trastuzumab Regimen for Treating CNS Metastases in Patients With HER2+ Breast Cancer

Clinical Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
A phase II study of atezolizumab, pertuzumab, and high-dose trastuzumab for central nervous system metastases in patients with HER2-positive breast cancer
Clin. Cancer Res 2024 Sep 03;[EPub Ahead of Print], A Giordano, PU Kumthekar, Q Jin, B Binboga Kurt, S Ren, T Li, JP Leone, EA Mittendorf, AM Pereslete, L Sharp, R Davis, M DiLullo, N Tayob, EL Mayer, EP Winer, SM Tolaney, NU Lin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading